

Synthesis and Evaluation of Anti-acetylcholinesterase Activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)Isoindoline-1,3-dione Derivatives with Potential Anti-Alzheimer Effects

Alireza Aliabadi ^{1, 2*}, Alireza Foroumadi ³, Ahmad Mohammadi-Farani ^{1, 4}, Mahdi Garmsiri Mahvar ^{2, 5}

¹Novel Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

⁴Department of Pharmacology, Toxicology and Medical Services, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁵Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

ARTICLE INFO

Article type:
Original article

Article history:
Received: Jun 29, 2012
Accepted: Jan 10, 2013

Keywords:
Acetylcholinesterase
Alzheimer
Phthalimide
Synthesis

ABSTRACT

Objective(s): Alzheimer's disease (AD) is a neurodegenerative disorder in elderly patients. Decrease in cholinergic neurotransmission is the main known cause in the pathophysiology of the disease. Improvement and potentiation of the cholinergic system could be beneficial for treatment of the AD. Acetylcholinesterase inhibitors such as donepezil can enhance the duration of action of acetylcholine (ACh) and therefore, through this mechanism improve the symptoms of AD. **Materials and Methods:** In the current study, based on the potential inhibitory activity of phthalimide derivatives towards acetylcholinesterase enzyme, a new series of phthalimide-based compounds were synthesized (**4a-4e**) and anti-acetylcholinesterase effect was assessed using Ellman's test. Compound **4b** with 4-Fluorophenyl moiety was the most potent derivative in this series ($IC_{50} = 16.42 \pm 1.07 \mu M$). It was shown that, none of the synthesized compounds showed superior inhibitory potency compared to donepezil ($0.41 \pm 0.09 \mu M$) as a reference drug. **Conclusion:** The new synthesized phthalimide based analogs could function as potential acetylcholinesterase inhibitors. Further studies are necessary for development of potent analogs.

► Please cite this paper as:

Foroumadi AR, Mohammadi-Farani A, Garmsiri Mahvar M, Aliabadi AR. Synthesis and Evaluation of Anti-acetylcholinesterase Activity of 2-(2-(4-(2-Oxo-2-phenylethyl) piperazin-1-yl) ethyl) Isoindoline-1,3-dione Derivatives with Potential Anti-Alzheimer Effects. Iran J Basic Med Sci; 2013; 16: 1049-1054.

Introduction

Alzheimer's disease (AD) as an age-related and neurodegenerative disease destroys patient's memory and cognition and also affects the communication ability of the patient. AD is the most common and the most prevalent cause of dementia with ageing. It is responsible for 50% cases of dementia in geriatric patients over 65 years of age. This progressive disorder also affects the ability to perform daily activities, doing judgment, learning and etc (1-5). Decrease in the functional capacity will result in death, approximately 8-10 years after the initiation of the symptoms of the illness (6).

A progressive reduction in cholinergic neurons in some areas of the brain such as cortex and hippocampus is related to the deficits in memory and cognitive function in Alzheimer's disease (AD). This

observation led to the development of therapeutic agents that function as acetylcholinesterase (AChE) inhibitors in central nervous system. In fact, these agents prolong the duration of action of acetylcholine (ACh) and render symptomatic relief in this disorder (7-11). The administration of acetylcholinesterase inhibitors as first generation anti-Alzheimer drugs has beneficial effects on cognitive, functional and behavioral symptoms of the disease (2, 12). Several acetylcholinesterase inhibitors are available currently in the market such as donepezil (benzylpiperidine derivative), rivastigmine (carbamate derivative), tacrine (aminoacridine derivative) and galantamine (a natural alkaloid extracted from the herb) (13, 14) (Figure 1).

*Corresponding author: Alireza Aliabadi. Department of Medicinal Chemistry, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. Tel: +98-831-4276481; Fax: +98-831-4276493; email: aliabadi.alireza@gmail.com




Figure 1. Structures of some current acetylcholinesterase inhibitors in the market




Figure 2. Structure of a lead compound (compound A) and the logic and process for design of new derivatives

Recently, some investigations have been reported the potential anticholinesterase activity of phthalimide derivatives (15-20). In the present study, we have focused on the structure of donepezil and therefore a new series of donepezil like derivatives based on phthalimide structure were designed as an acetylcholinesterase inhibitor with potential anti-Alzheimer effect. Furthermore, according to the report of Sugimoto and colleagues, the design of new derivatives was carried out via the bioisosteric replacement of piperidine with piperazine ring as well as benzyl moiety with various phenacyl groups (Figure 2).

Materials and Methods

Chemistry

Chemical substances, reagents and solvents were prepared from the commercial vendors such as Merck and Sigma-Aldrich companies. ¹H-NMR spectra were recorded using a Bruker 400 MHz spectrometer in deuterated solvents, and chemical shifts are expressed as δ (ppm) with tetramethylsilane (TMS) as internal standard. The IR spectra were obtained on a Shimadzu 470 spectrophotometer using potassium bromide (KBr) disks. Melting points were determined using Electrothermal 9001 elemental analyzer apparatus and are uncorrected. The mass spectra were run on a Finigan TSQ-70 spectrometer (Finigan, USA) at 70 eV.


Synthesis of 2-(2-(piperazin-1-yl)ethyl)isoindoline-1,3-dione (3)

In a flask 3 g (20 mmol) of phthalic anhydride, 2.6 ml (20 mmol) *N*-amnioethylpiperazine and 2.9 ml (20 mmol) triethylamine (Et₃N) were mixed in 40 ml of toluene solvent. The reaction mixture was refluxed for 24 hr and the termination of reaction and formation of the desired product was confirmed by thin layer chromatography. The discoloration of the reaction medium and formation of a yellow precipitate was also an indicator of the progress of the reaction. Then, toluene was evaporated under reduced pressure using rotary evaporator apparatus and the obtained yellow viscose and oily residue was washed several times by ethyl acetate (EtOAc) and diethyl ether (Et₂O) (19).

¹H NMR (CDCl₃, 400 MHz) δ (ppm): 2.37 (m, Piperazine), 2.54 (m, Piperazine), 3.22 (t, phthalimide-CH₂-CH₂-piperazine), 3.44 (t, phthalimide-CH₂-CH₂-piperazine), 4.73 (s, NH, Piperazine), 7.35-7.85 (m, 4H, Phthalimide). IR (KBr, cm⁻¹): 3380, 3330, 3157, 3111, 2924, 1730, 1681, 1521, 1489, 1458, 1328, 1303, 1186, 1143, 1035, 910, 750, 710. MS (*m/z*, %): 259 (M⁺, 10), 224 (30), 174 (30), 160 (60), 149 (85), 99 (100), 70 (70), 57 (65), 41 (40).

General procedure for synthesis of compounds 4a-4e

In a flat bottom flask, equimolar quantities of compound 3, triethylamine (Et₃N) and appropriate



Scheme 1. Synthetic pathway for compounds **4a-4e**

derivative of aryl acyl chloride were mixed in acetonitrile (CH_3CN) solvent. The reaction was carried out under reflux condition for 24 hr. The reaction end was determined and confirmed using thin layer chromatography (TLC). After completion of the reaction, acetonitrile was evaporated under reduced pressure by rotary evaporator apparatus. Then, ethyl acetate / water were added to the residue and the aqueous layer was discarded. The organic phase was washed two times by sodium bicarbonate 5% and also brine. Anhydrous sodium sulfate was applied for drying of the ethyl acetate. The sodium sulfate was removed by filtration and the organic layer was evaporated under reduced pressure. Diethyl ether and *n*-hexane were applied for washing the obtained precipitate.

2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (4a)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 1.33 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 2.5-3.37 (m, 8H, Piperazine), 3.00 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 3.99 (s, 2H, CH_2CO -Phenyl), 7.22 (m, 5H, Phenyl), 7.46 (m, 2H, Phthalimide), 7.68 (m, 2H, Phthalimide). IR (KBr, cm^{-1}) ν : 3055 (C-H, Stretch, Aromatic), 2927 (C-H, Stretch, Aliphatic), 1712 (C=O, Stretch). MS (m/z , %): 378 (M^+ , 70), 272 (100), 257 (10), 231 (12), 217 (12), 203 (10), 174 (20), 160 (15), 125 (15), 105 (40), 98 (80), 77 (30), 56 (25).

2-(2-(4-(2-(4-Fluorophenyl)-2-oxoethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (4b)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 3.00-4.15 (m, 12H, Aliphatic), 4.34 (s, 2H, CH_2 -CO), 7.21 (m, 4H, 4-Fluorophenyl), 7.48-7.91 (m, 4H, Phthalimide). IR (KBr, cm^{-1}) ν : 3057 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Aliphatic), 1712 (C=O, Stretch). MS (m/z , %): 396 (30), 272 (80), 260 (45), 174 (15), 123 (60), 99 (100), 76 (15), 56 (25).

2-(2-(4-(2-(3-Chlorophenyl)-2-oxoethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (4c)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 1.25 (m, 2H, phthalimide- CH_2 - CH_2 -piperazine), 3.04-4.10 (m,

12H, Aliphatic), 7.58 (m, 4H, 3-Chlorophenyl), 7.77 (m, 2H, Phthalimide), 7.99 (m, 2H, Phthalimide). IR (KBr, cm^{-1}) ν : 3074 (C-H, Stretch, Aromatic), 2924 (C-H, Stretch, Aliphatic, Asymmetric), 2854 (C-H, Stretch, Aliphatic, Symmetric), 1708 (C=O, Stretch). MS (m/z , %): 413 (M^+ , 2, 2), 411 (M^+ , 5), 314 (20), 312 (5), 310 (35), 292 (75), 268 (10), 249 (5), 235 (10), 205 (45), 139 (100), 75 (55).

2-(2-(4-(2-(2,4-Dichlorophenyl)-2-oxoethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (4d)


$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 1.27 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 3.09 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 3.51 (m, 4H, Piperazine), 3.82 (m, 6H, Aliphatic), 7.53 (m, 3H, 2,4-Dichlorophenyl), 7.79 (m, 4H, Phthalimide). IR (KBr, cm^{-1}) ν : 3059 (C-H, Stretch, Aromatic), 2927 (C-H, Stretch, Aliphatic), 1708 (C=O, Stretch). MS (m/z , %): 446 (M^+ , 2), 432 (5), 414 (5), 364 (5), 301 (10), 288 (25), 272 (80), 260 (100), 217 (12), 203 (20), 174 (80).

2-(2-(4-(2-(Naphthalen-2-yl)-2-oxoethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione (4e)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ (ppm): 1.33 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 2.57 (m, 4H, Piperazine), 3.13 (t, 2H, phthalimide- CH_2 - CH_2 -piperazine), 3.75 (m, 6H, Aliphatic), 7.30-8.58 (m, 7H, Naphthyl), 7.78 (m, 2H, Phthalimide), 7.97 (m, 2H, Phthalimide). IR (KBr, cm^{-1}) ν : 3055 (C-H, Stretch, Aromatic), 2931 (C-H, Stretch, Aliphatic), 1708 (C=O, Stretch). MS (m/z , %): 427 (M^+ , 10), 272 (95), 203 (10), 174 (25), 155 (40), 127 (75), 99 (100), 76 (15), 56 (50).

Anti-acetylcholinesterase assay

Lyophilized powder of acetylcholinesterase from electric eel source (AChE, E.C. 3.1.1.7, Type V-S, 1000 unit) was purchased from Sigma-Aldrich (Steinheim, Germany). 5,5'-Dithiobis-(2-nitrobenzoic acid, DTNB), potassium dihydrogen phosphate (KH_2PO_4), dipotassium hydrogen phosphate (K_2HPO_4), potassium

Table 1. Physicochemical properties of synthesized compounds

Compound	Ar	Closed formula	MW (g/mol)	m.p (°C)	Yield (%)
3	-	C ₁₄ H ₁₇ N ₃ O ₂	259	105-109	61
4a	Phenyl	C ₂₂ H ₂₃ N ₃ O ₃	377.4	164	83
4b	4-Fluorophenyl	C ₂₂ H ₂₂ FN ₃ O ₃	395.4	120	62
4c	3-Chlorophenyl	C ₂₂ H ₂₂ ClN ₃ O ₃	411.9	148	73
4d	2,4-Dichlorophenyl	C ₂₂ H ₂₁ Cl ₂ N ₃ O ₃	446.3	131	69
4e	2-Naphthyl	C ₂₆ H ₂₅ N ₃ O ₃	427.5	133	76

hydroxide (KOH), sodium hydrogen carbonate (NaHCO₃), and acetylthiocholine iodide were purchased from Fluka (Buchs, Switzerland). Spectrophotometric measurements were run on a Cecil BioAquarius CE 7250 Double Beam Spectrophotometer.

Compounds **4a-4e** were dissolved in a mixture of 20 ml distilled water and 5 ml methanol and then diluted in 0.1 M KH₂PO₄/K₂HPO₄ buffer (pH 8.0) to yield a final concentration range. According to the literature, the Ellman test was performed for assessment of the anticholinesterase activity of intended compounds *in vitro*. To achieve 20-80% inhibition of AChE activity five different concentrations of each compound were tested. Compounds **4a-4e** were added to the assay solution and preincubated at 25°C with the enzyme for 15 min followed by adding 0.075 M of acetylthiocholine iodide. After rapid and immediate mixing the change of absorption was measured at 412 nm. The blank reading contained 3 ml buffer, 200 μl water, 100 μl DTNB and 20 μl substrate. The reaction rates were calculated, and the percent inhibition of test compounds was determined. Each concentration was analyzed in triplicate, and IC₅₀ ± SD values were determined graphically from inhibition curves (log inhibitor concentration vs percent of inhibition) (21, 22).

Results

Chemistry

Table 1 shows all compounds **3** and **4a-4e** synthesized with high yield. Compound **3** was prepared with 61% and a range of 62-83% of yields was obtained from final compounds. All synthesized compounds **4a-4e** were afforded as orange powders and compound **3** as yellowish powder. Related melting points were measured and a range of 120-164°C was recorded in this series. All final compounds **4a-4e** rendered a sharp melting point. Whereas, compound **3** exhibited at 105-109°C a ranged melting point.

Enzymatic assay

Inhibitory potency of final compounds **4a-4e** was evaluated towards acetylcholinesterase enzyme.


Ellman test protocol was applied and the inhibitory potency of tested compounds was reported in Table 2 as IC₅₀ ± SD. Donepezil was used as reference drug and it demonstrated a high inhibitory effect (0.41 ± 0.09 μM) towards acetylcholinesterase. A range of 16.42 ± 1.07 μM to 63.03 ± 4.06 μM was obtained for tested derivatives. All of them exerted a lower inhibitory activity than donepezil.

Discussion

Chemistry

A new series of donepezil-like analogs based on the phthalimide structure were synthesized. Piperazine moiety was also introduced into these compounds as bioisosteric replacement of the piperidine ring in donepezil. The intermediate compound **3** was prepared through a Gabriel synthetic procedure of phthalimide. In fact, phthalimic anhydride was treated under reflux condition by *N*-amnioethylpiperazine (**2**) in toluene solvent. The reaction was run for 24 hr and intended product (compound **3**) were obtained and used for synthesis of **4a-4e** derivatives. Final compounds **4a-4e** was obtained in a range of 62-83% yields. The lowest yield was then observed for compound **4b** with 4-fluorophenyl moiety and compound **4a** with phenyl substituent was obtained with highest yield in this series.

¹H NMR spectra were obtained in CDCl₃ as deuterated solvent and compared to tetramethylsilane (TMS) as internal standard. IR spectra were recorded using KBr disk and the presence of carbonyl peak was a sign for synthesized compounds. Mass spectra were obtained and the most frequent peaks (fragments) were reported. Fragments with 272 *m/z* and 174 *m/z* were the most probable fragments and were observed in the most cases. Melting points were calculated using melting point analyser on open capillary tubes. Compound **4b** with 4-fluorophenyl moiety showed the lowest melting point at 120°C. Nevertheless, compound **4a** with phenyl substituent exerted the highest melting point at 164°C.

Table 2. Results of acetylcholinesterase inhibitory activity of compounds **4a-4e** (IC₅₀, μM)

Compound	Ar	IC ₅₀ (μM ± SD)
4a	Phenyl	45.56 ± 2.78
4b	4-Fluorophenyl	16.42 ± 1.07
4c	3-Chlorophenyl	28.19 ± 2.3
4d	2,4-Dichlorophenyl	63.03 ± 4.06
4e	2-Naphthyl	40.49 ± 2.47
Donepezil	-	0.41 ± 0.09

Enzymatic assay

The anti-acetylcholinesterase activity of final compounds **4a-4e** was investigated towards acetylcholinesterase. The related acetylcholinesterase enzyme that applied in this test was with electric eel source and the obtained results (IC₅₀) were compared to donepezil as a reference drug. It was shown that, none of the synthesized compounds exerted superior activity in comparison with donepezil. Compound **4b** with 4-fluorophenyl substituent was the best inhibitor (IC₅₀ = 16.42 ± 1.07) of acetylcholinesterase enzyme in this series. Whereas, compound **4d** with 2,4-dichlorophenyl group exhibited the lowest inhibitory potency towards acetylcholinesterase. In General, introduction of an electron withdrawing group such as chlorine (compound **4c**) and fluorine (**4b**) enhanced the inhibitory effects of these compounds. More electronegative groups caused more raise in potency. Insertion of chlorine atoms concurrently at positions *ortho* and *para* of the phenyl ring as applied in compound **4d** was so detrimental for activity. It can be proposed that steric hindrance may also be an essential factor for ligand-receptor interaction. Fusion of a second phenyl moiety to the phenyl ring (naphthyl group) caused an increase in activity compared to phenyl. However, as mentioned above for compound **4d**, naphthyl moiety also can cause a steric hindrance and eventually decreased the activity.

Conclusion

Compounds **4a-4e** were synthesized as new analogs of donepezil based on phthalimide substructure. All of the presented derivatives in this research demonstrated inferior potency than donepezil in Ellman test. Although synthesized compounds rendered low anticholinesterase activity, these derivatives especially compound **4b** could be suggested as potential inhibitors of acetylcholinesterase enzyme.

Acknowledgment

Authors acknowledge from the research deputy of Kermanshah University of Medical Sciences for

financial support. This work was performed in partial fulfillment of the requirement for PharmD of Mr Mahdi Garmsiri Mahvar.

References

- Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, *et al*. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. *Adv Drug Del Rev* 2008; 60:1463-1470.
- Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. *Lancet Neurol* 2003; 2:539-547.
- Ucar G, Gokhan N, Yesilada A, Bilgin AA. 1-*N*-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. *Neurosci Lett* 2005; 382:327-331.
- Vitorović-Todorović MD, Juranić IO, Mandić LM, Drakulic BJ. 4-Aryl-4-oxo-*N*-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. *Bioorg Med Chem* 2010; 18:1181-1193.
- Yu L, Cao R, Yi W, Yan Q, Chen C, Ma L, *et al*. Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase. *Bioorg Med Chem Lett* 2010; 20:3254-3258.
- Hassan Khan M. Molecular interactions of cholinesterases inhibitors using *in silico* methods: current status and future prospects. *New Biotechnol* 2009; 5:331-346.
- Weinstock M, Groner E. Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity. *Chem Biol Interact* 2008; 175:216-221.
- Zhang J, Zhu D, Sheng R, Wu H, Hu Y, Wang F, *et al*. BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. *Eur J Pharmacol* 2009; 613:1-9.
- Mustazza C, Borioni A, Rosaria Del Giudice M, Gatta F, Ferretti R, *et al*. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease. *Eur J Med Chem* 2002; 37:91-109.
- Kryger G, Israel S, Sussman JL. Structure of acetylcholinesterase complexed with E200 (Aricept®): implications for the design of new anti-Alzheimer drugs. *Structure* 1999; 3:297-307.
- Araújo JQ, Araújo de Brito M, Bôas Hoelz LV, de Alencastro RB, Castro HC, Rodrigues CR, *et al*. Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE). *Eur J Med Chem* 2011; 46:39-51.
- Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: From 3D structure to function. *Chem Biol Interact* 2010; 187:10-22.

13. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, *et al.* Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. *Eur J Pharmacol* 2004; 486:9-17.
14. Nukoolkarn SV, Saen-oon S, Rungrotmongkol T, Hannongbua S, Ingkaninan K, Suwanborirux K. Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge *Petrosia n. sp.* *Bioorg Med Chem* 2008; 16:6560-6567.
15. Kapková P, Alptüzün V, Frey P, Erciyasb E, Holzgrabe U. Search for dual function inhibitors for Alzheimer's disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their A β fibril formation inhibition capacity. *Bioorg Med Chem* 2006; 14:472-478.
16. Alonso D, Dorransoro I, Rubio L, Munoz P, García-Palomero E, Del Monte M, *et al.* Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. *Bioorg Med Chem* 2005; 13:6588-6597.
17. Mary A, Zafiarisoa Renko D, Guillou C, Thal C. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. *Bioorg Med Chem* 1998; 6:1835-1850.
18. Zhao Q, Yang G, Mei X, Yuan H, Ning J. Novel acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of phthalimide alkyloxyphenyl *N,N*-dimethylcarbamate derivatives. *Pestic Biochem Phys* 2009; 95:131-134.
19. Ragavendran JV, Sriram D, Patel SK, Reddy IV, Bharathwajan N, Stables J. Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore. *Eur J Med Chem* 2007; 42:146-151.
20. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and related compounds. *J Med Chem* 1996; 38:4821-4829.
21. Nadri H, Pirali-Hamedani M, Shekarchi M, Abdollahi M, Sheibani V, Amanlou M, *et al.* Design, Synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidin) methyl) pyridinium derivatives. *Bioorg Med Chem* 2010; 18:6360-6366.
22. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961; 7:88-95.

Archive of SID